Wisconsin-based NorthStar Medical Radioisotopes just got an $11.75 million in government funding to develop new isotope-development technologies for use in medical imaging.
Right now, the radioisotopes used most commonly in medical imaging diagnostics are developed using weapon-grade uranium – and outside of the U.S. This can lead to chronic product shortages as well as safety and national security concerns – which is why the government is funneling money into a new development method of isotope development.
Funding comes from the U.S. Department of Energy’s nuclear division to develop a way to produce the medical radioisotope molybdenum-99 (Mo-99) without using highly enriched uranium. Mo-99 is the parent isotope of technetium-99m (Tc-99m), which is the most widely used radioisotope in medical imaging diagnostics.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Specifically, $8.86 million will support NorthStar’s neutron capture production process, and $2.89 million will be used for its accelerator production process.
